Home LiteratureArticle Details
PMID: 7734307 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Serum levels of interleukin 6 in patients with lung cancer.

British journal of cancer ·Vol. 71 ·No. 5 ·1995-05-00 ·Pages 1095-8

Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, Ogura T

Abstract

Serum interleukin 6 (IL-6) levels were measured in 75 patients with lung cancer and in 20 patients with benign lung diseases. IL-6 was detectable in 29 patients with lung cancer (39%), but was not detectable in any of the patients with benign lung diseases. Serum C-reactive protein levels and plasma fibrinogen levels were significantly higher and serum albumin concentration was significantly lower in lung cancer patients with detectable serum IL-6 levels than in those without detectable serum IL-6 levels and in patients with benign lung diseases. On the other hand, no significant difference was observed in blood platelet counts in these three groups. Moreover, serum IL-6 levels were not significantly different in lung cancer patients with or without clinically demonstrated distant metastasis. These results suggest that IL-6 may be a mediator of various reactions including an inflammatory response in lung cancer patients.

MeSH Terms
Adult Aged Aged, 80 and over C-Reactive Protein/metabolism Female Fibrinogen/metabolism Humans Interleukin-6/blood Lung Diseases/blood Lung Neoplasms/blood Male Middle Aged Platelet Count Serum Albumin/metabolism
Chemicals
Interleukin-6 Serum Albumin Fibrinogen C-Reactive Protein
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Yanagawa H
Third Department of Internal Medicine, University of Tokushima, School of Medicine, Japan.
Sone S
Takahashi Y
Haku T
Yano S
Shinohara T
Ogura T
References (34)
34 references, click to expand
  1. Serum levels of interleukin-6 and acute phase responses.
    Lancet. 1987 Oct 17;2(8564):921 PMID: 2889120
  2. B cell growth and differentiation induced by supernatants of transformed epithelial cell lines.
    Eur J Immunol. 1986 Aug;16(8):1017-9 PMID: 3091374
  3. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.
    Nature. 1988 Mar 3;332(6159):83-5 PMID: 3258060
  4. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides.
    Arthritis Rheum. 1988 Jun;31(6):784-8 PMID: 3260102
  5. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha.
    Eur J Immunol. 1988 Aug;18(8):1259-64 PMID: 3138137
  6. Multiple forms of IFN-beta 2/IL-6 in serum and body fluids during acute bacterial infection.
    J Immunol. 1989 Feb 1;142(3):948-53 PMID: 2536416
  7. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes.
    FEBS Lett. 1989 Jan 2;242(2):237-9 PMID: 2464504
  8. The biology of interleukin-6.
    Blood. 1989 Jul;74(1):1-10 PMID: 2473791
  9. A possible autocrine role for interleukin-6 in two lymphoma cell lines.
    Blood. 1989 Aug 1;74(2):798-804 PMID: 2787680
  10. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas.
    FEBS Lett. 1989 Jul 3;250(2):607-10 PMID: 2787758
  11. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro.
    Proc Natl Acad Sci U S A. 1989 Aug;86(15):5953-7 PMID: 2788282
  12. Infection with HIV is associated with elevated IL-6 levels and production.
    J Immunol. 1990 Jan 15;144(2):480-4 PMID: 2295799
  13. Stimulation of thrombopoiesis in mice by human recombinant interleukin 6.
    J Clin Invest. 1990 Apr;85(4):1242-7 PMID: 2318977
  14. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
    Cancer Res. 1992 Jun 15;52(12):3317-22 PMID: 1596890
  15. Interleukin-6 and renal cell cancer: production, regulation, and growth effects.
    Cancer Immunol Immunother. 1992;35(2):97-105 PMID: 1596939
  16. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity?
    Clin Exp Immunol. 1992 Oct;90(1):106-10 PMID: 1395090
  17. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.
    J Clin Oncol. 1993 Mar;11(3):499-506 PMID: 7680375
  18. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta.
    Blood. 1993 Apr 15;81(8):2076-84 PMID: 8386026
  19. Differentiation and proliferation of hematopoietic stem cells.
    Blood. 1993 Jun 1;81(11):2844-53 PMID: 8499622
  20. Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism.
    Cancer Res. 1993 Sep 15;53(18):4175-81 PMID: 8364912
  21. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction.
    Lymphokine Cytokine Res. 1993 Aug;12(4):225-30 PMID: 8218595
  22. Phagocyte function and cytokine production in community acquired pneumonia.
    Thorax. 1994 Feb;49(2):107-11 PMID: 8128397
  23. Autonomous expressions of cytokine genes by human lung cancer cells and their paracrine regulation.
    Jpn J Cancer Res. 1994 Feb;85(2):179-86 PMID: 8144399
  24. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma.
    Eur J Cancer. 1994;30A(2):162-7 PMID: 8155390
  25. In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets.
    Blood. 1990 Apr 15;75(8):1602-5 PMID: 2328312
  26. Human glioblastoma cells release interleukin 6 in vivo and in vitro.
    Cancer Res. 1990 Oct 15;50(20):6683-8 PMID: 2208133
  27. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures.
    Cancer Res. 1990 Nov 1;50(21):6959-65 PMID: 2208162
  28. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.
    J Clin Invest. 1991 Jul;88(1):239-47 PMID: 1647416
  29. Constitutive production of granulocyte colony-stimulating factor and interleukin-6 by a human lung cancer cell line, KSNY: gene amplification and increased mRNA stability.
    Eur J Haematol. 1991 Aug;47(2):128-33 PMID: 1716216
  30. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection.
    J Immunol. 1992 Apr 1;148(7):2175-80 PMID: 1545125
  31. Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
    J Clin Invest. 1992 May;89(5):1681-4 PMID: 1569207
  32. IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2.
    Clin Exp Immunol. 1992 May;88(2):207-12 PMID: 1315227
  33. Nutrition in the critically ill patient.
    Anesthesiology. 1977 Aug;47(2):181-94 PMID: 406811
  34. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.
    Proc Natl Acad Sci U S A. 1987 Dec;84(24):9035-9 PMID: 3501121
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
DOI
10.1038/bjc.1995.212
Published
1995-05-00
Pages
1095-8
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2033769
Subset
IM
External Links
PubMed source DOI: 10.1038/bjc.1995.212 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2